Device for treating an individual suffering from cardiac insufficiency, cardiac arrest, circulatory arrest or stroke

• US 10,086,139 B2
• Filed: 07/19/2016
• Issued: 10/02/2018
• Est. Priority Date: 10/12/2009
• Status: Active Grant

• Current Assignee: ResuSciTec GmbH
• Original Assignee: ResuSciTec GmbH
• Inventors: Beyersdorf, Friedhelm
• Primary Examiner(s): Klein, Benjamin
• Application Number:
  US15/213,716
• Publication Number:
  US 20170035967A1
• Time in Patent Office: 805 Days
• CPC Class Codes: A61B 5/14539 for measuring pH
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/14557 specially adapted to extracorporeal circuits
• CPC Class Codes: A61M 1/34 Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
• CPC Class Codes: A61M 1/3639 Blood pressure control, pressure transducers specially adapted therefor
• CPC Class Codes: A61M 1/3666 Cardiac or cardiopulmonary bypass, e.g. heart-lung machines
• CPC Class Codes: A61M 1/3687 Chemical treatment A61M1/3675 takes precedence
• CPC Class Codes: A61M 1/369 Temperature treatment
• CPC Class Codes: A61M 2005/006 for gases, e.g. CO2
• CPC Class Codes: A61M 2005/14272 for emergency, field or home use, e.g. self-contained kits to be carried by the doctor
• CPC Class Codes: A61M 2202/0208 Oxygen
• CPC Class Codes: A61M 2202/04 Liquids
• CPC Class Codes: A61M 2202/0468 non-physiological
• CPC Class Codes: A61M 2202/0486 Glucose
• CPC Class Codes: A61M 2202/06 Solids
• CPC Class Codes: A61M 2202/07 Proteins
• CPC Class Codes: A61M 2205/3368 Temperature
• CPC Class Codes: A61M 2205/52 with memories providing a history of measured variating parameters of apparatus or patient
• CPC Class Codes: A61M 2205/75 with filters
• CPC Class Codes: A61M 2210/125 Heart
• CPC Class Codes: A61M 2230/005 : Parameter used as control input for the apparatus
• CPC Class Codes: A61M 2230/20 : Blood composition characteristics
• CPC Class Codes: A61M 2230/201 : Glucose concentration
• CPC Class Codes: A61M 2230/202 : partial carbon oxide pressure, e.g. partial dioxide pressure (P-CO2)
• CPC Class Codes: A61M 2230/205 : partial oxygen pressure (P-O2)
• CPC Class Codes: A61M 2230/208 : pH-value
• CPC Class Codes: A61M 2230/30 : Blood pressure A61M2230/04 takes precedence
• CPC Class Codes: A61M 2230/50 : Temperature
• CPC Class Codes: A61M 2250/00 : Specially adapted for animals
• CPC Class Codes: A61M 5/1408 : in parallel, e.g. manifolds, sequencing valves access sites A61M39/02; tube connectors A61M39/10
• CPC Class Codes: A61M 5/142 : Pressure infusion, e.g. using pumps
• CPC Class Codes: A61M 5/16827 : controlling delivery of multiple fluids, e.g. sequencing, mixing or via separate flow-paths infusion of multiple fluids without using a controller A61M5/1407
• CPC Class Codes: A61M 5/1723 : using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61M 5/44 : having means for cooling or heating the devices or media
• CPC Class Codes: A61P 7/08 : Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04

Abstract

The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising a blood withdrawal device (BE) that is applied to the individual (P), an analysis unit (BA) which is directly or indirectly connected to the blood withdrawal device for detecting a blood analysis result (BAE) providing at least one characteristic of the blood, directly or indirectly connected to a blood return device (BR) that is applied to the individual (P) and is designed to deliver a substance to the individual via the return device (BR).

Claims

1. A method for providing treatment of cardiac arrest by withdrawing blood from a patient'"'"'s or an animal'"'"'s circulatory system during the cardiac arrest by first introducing a reperfusion solution containing at least one substance into the circulatory system and then introducing modified blood into the circulatory system formed by addition of the at least one substance or at least one other substance to the withdrawn blood to provide whole body reperfusion of the circulatory system during the treatment of the cardiac arrest with the cardiac arrest occurring before the start of treatment comprising:

using an automated blood analysis during the treatment of the cardiac arrest to determine a plurality of parameters of the blood including at least pO₂, pCO₂ and pH representing a current condition of the patient or animal during the treatment of the cardiac arrest and providing an output representing the parameters during the treatment;

storing during the treatment of the cardiac arrest at least two substances from which the at least one substance or the at least one other substance is selected for treatment of the cardiac arrest;

selecting, based on the automated analysis of the determined parameters, a type and quantity of the at least one substance or the at least one other substance to be withdrawn from the storage; and

introducing during the treatment of the cardiac arrest first the selected at least one substance into the circulatory system and then introducing the modified blood containing the at least one substance or the at least one other substance into the circulatory system to provide the whole body reperfusion of the circulatory system during the treatment of the cardiac arrest that lessens or prevents ischemic tissue damage during the treatment of the cardiac arrest.

2. A method in accordance with claim 1, wherein:

the introducing of the selected at least one substance or the at least one other substance is by pumping the at least one substance or the modified blood into the circulatory system.

3. A method in accordance with claim 1, wherein:

the selected at least one substance or the at least one other substance is mixed with the withdrawn blood to form the modified blood.

4. A method in accordance with claim 2, wherein:

the selected at least one substance or the at least one other substance is mixed with the withdrawn blood to form the modified blood.

5. A method in accordance with claim 1, wherein:

the introducing of the selected at least one substance or the at least one other substance includes providing a regulated flow of at least the modified blood into the circulatory system.

6. A method in accordance with claim 2, wherein:

the introducing of the selected at least one substance or the at least one other substance includes providing a regulated flow of at least the modified blood into the circulatory system.

7. A method in accordance with claim 3, wherein:

the introducing of the selected at least one substance or the at least one other substance includes providing a regulated flow of at least the modified blood into the circulatory system.

8. A method in accordance with claim 4, wherein:

the introducing of the selected at least one substance or the at least one other substance includes providing a regulated flow of at least the modified blood into the circulatory system.

9. A method in accordance with claim 1, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

the selecting of the type and quantity of the at least one substance or the at least one other substance is also based on the representation.

10. A method in accordance with claim 2, comprising:

monitoring at least one physiological parameter during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

the selecting of the type and quantity of the at least one substance or the at least one other substance is also based on the representation.

11. A method in accordance with claim 3, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

the selecting of the type and quantity of the at least one substance or the at least one other substance is also based on the representation.

12. A method in accordance with claim 4, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

the selecting of the type and quantity of the at least one substance or the at least one other substance is also based on the representation.

13. A method in accordance with claim 5, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

the selecting of the type and quantity of the at least one substance or the at least one other substance is also based on the representation.

14. A method in accordance with claim 6, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

the selecting of the type and quantity of the at least one substance or the at least one other substance is also based on the representation.

15. A method in accordance with claim 7, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

the selecting of the type and quantity of the at least one substance or the at least one other substance is also based on the representation.

16. A method in accordance with claim 8, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

the selecting of the type and quantity of the at least one substance or the at least one other substance is also based on the representation.

17. A method in accordance with claim 1, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

18. A method in accordance with claim 2, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

19. A method in accordance with claim 3, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

20. A method in accordance with claim 4, wherein:

the storing stores a plurality of substances from which selection is solid, liquid or gaseous form for treatment of the cardiac arrest.

21. A method in accordance with claim 5, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

22. A method in accordance with claim 6, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

23. A method in accordance with claim 7, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

24. A method in accordance with claim 8, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

25. A method in accordance with claim 9, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

26. A method in accordance with claim 10, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

27. A method in accordance with claim 11, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

28. A method in accordance with claim 12, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

29. A method in accordance with claim 13, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

30. A method in accordance with claim 14, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

31. A method in accordance with claim 15, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

32. A method in accordance with claim 16, wherein:

the storing stores a plurality of substances from which selection is made;

wherein the plurality of substances are in at least one of solid, liquid or gaseous form for treatment of the cardiac arrest.

33. A method in accordance with claim 1, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

34. A method in accordance with claim 2, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

35. A method in accordance with claim 3, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

36. A method in accordance with claim 4, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

37. A method in accordance with claim 5, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

38. A method in accordance with claim 6, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

39. A method in accordance with claim 7, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

40. A method in accordance with claim 8, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

41. A method in accordance with claim 9, wherein:

the at least one substance or at least one other substance comprises at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing the leukocyte count, osmotically-active substances, including salts, glucoses and proteins.

42. A method in accordance with claim 9, wherein:

the monitoring includes monitoring the at least one physiological parameter during the cardiac arrest which comprises at least one of mean arterial pressure, central nervous pressure, pulmonary artery pressure, oxygen saturation, and blood temperature.

43. A method in accordance with claim 1, wherein:

the automated blood analysis of the determined parameters includes at least one parameter of the blood comprising at least one of potassium content, sodium content, calcium content, base excess, lactate value and glucose content.

44. A method in accordance with claim 9, wherein:

the automated blood analysis of the determined parameters includes at least one parameter of the blood comprising at least one of potassium content, sodium content, calcium content, base excess, lactate value and glucose content.

45. A method in accordance with claim 1, comprising:

passing the modified blood through a blood flow path disposed outside the circulatory system between a point of withdrawal of the blood from the circulatory system during the cardiac arrest and a point of return of at least the modified blood into the circulatory system during the cardiac arrest.

46. A method in accordance with claim 9, comprising:

passing the modified blood through a blood flow path disposed outside the circulatory system between a point of withdrawal of the blood from the circulatory system during the cardiac arrest and a point of return of at least the modified blood into the circulatory system during the cardiac arrest.

47. A method in accordance with claim 1, comprising:

using a heat exchanger disposed in a blood flow path between a point of withdrawal of the blood from the circulatory system during the cardiac arrest and a point of return of at least the modified blood into the circulatory system to control temperature of the modified blood during the cardiac arrest.

48. A method in accordance with claim 9, comprising:

using a heat exchanger disposed in a blood flow path between a point of withdrawal of the blood from the circulatory system during the cardiac arrest and a point of return of at least the modified blood into the circulatory system to control temperature of the modified blood during the cardiac arrest.

49. A method in accordance with claim 1, comprising:

controlling, based on the determination of the parameters, at least one of pressure, flow rate and temperature of the modified blood flowing in the circulatory system during the whole body reperfusion of the circulatory system.

50. A method in accordance with claim 9, comprising:

controlling, based on the determination of the parameters, at least one of pressure, flow rate and temperature of the modified blood flowing in the circulatory system during the whole body reperfusion of the circulatory system.

51. A method in accordance with claim 44, comprising:

controlling, based on the determination of the parameters, an amount of oxygen in the modified blood flowing in the circulatory system during the whole body reperfusion of the circulatory system.

52. A method in accordance with claim 45, comprising:

controlling, based on the determination of the parameters, an amount of oxygen in the modified blood flowing in the circulatory system during the whole body reperfusion of the circulatory system.